News & Updates

Gastric cancer (GC) patients show an altered metabolic profile as compared with healthy individuals, a recent China study has found. A biomarker panel monitoring for nine metabolites can facilitate timely detection of GC.

First-line treatment of ALK-positive non-small-cell lung cancer (NSCLC) with lorlatinib improves progression-free survival (PFS) and reduces central nervous system (CNS) progression vs crizotinib, regardless of presence or absence of baseline brain metastases (BM), a post hoc analysis of the phase III CROWN trial has shown.

Low levels of sodium intake appear to worsen bone mineral density (BMD) and aggravate the risk of osteoporosis, a recent study has found.

In patients with of type 2 diabetes (T2D), glargine 300 U/mL (Gla-300) and degludec 100 U/mL (Deg-100) deliver similar improvements in glycaemic control, without increasing weight and hypoglycaemic events over 6 months of treatment, according to data from the retrospective RESTORE-2 NAIVE study.

A post hoc analysis of the SUSTAIN 6 and PIONEER 6 trials has found that semaglutide reduces incidence of any stroke in people with type 2 diabetes (T2D) at high cardiovascular (CV) risk vs placebo.

Serum concentrations of fibroblast growth factor-21 (FGF-21) are elevated in women with gestational diabetes mellitus (GDM), a recent study has found.